Germany, Italy, Spain, and France conduct well-documented primary immunodeficiency stem-cell trials within university immunology and paediatric immunology departments. Austria has several registered trials. United States capacity includes NIH-funded protocols and academic medical centres; however, FDA-approved gene-therapy alternatives may be more accessible. South Korea maintains active research. Israel conducts several registered immunodeficiency trials. Selection should prioritise centres with specialized immunology laboratory facilities, published immunological data, ClinicalTrials.gov registration, and discussion of approved alternatives (gene therapy, HSCT).
Primary immunodeficiency stem-cell treatment costs typically range €4,000–8,000 per infusion, reflecting the complexity of immunological assessment and monitoring. Fetal stem cells, when used, incur higher sourcing and manufacturing costs than placental MSCs, potentially exceeding €8,000 per cycle. Repeat infusions are common; multi-cycle protocols may total €15,000–25,000. Extensive immunological testing — T-cell subset enumeration, T-cell proliferation assays, antibody titers, vaccine responses — adds €1,500–3,000 to each cycle. Hospital-based immunology programmes typically charge €4,500–7,000; private boutique immune-therapy centres may exceed €8,000. European centres (Germany, Spain, Italy, Austria) generally offer more structured pricing than boutique clinics.
האם אני מועמד? → · Primary Immunodeficiency: full overview → · עלות חוסר חיסוניות ראשוני → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם